1 |
《中国心血管健康与疾病报告》编写组.《中国心血管健康与疾病报告2020》概述[J].中国心血管病研究,2021,19(7):582-590.
|
2 |
张强,程铖,徐日新,等.中性粒细胞与淋巴细胞比值对ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗后微循环障碍的预测价值[J/CD].中华危重症医学杂志(电子版),2020,13(5):351-355.
|
3 |
Du X, Patel A, Anderson CS, et al. Epidemiology of cardiovascular disease in China and opportunities for improvement: JACC International[J]. J Am Coll Cardiol, 2019, 73 (24): 3135-3147.
|
4 |
王天琪,肖浩,孟娜,等.河北省二三级医院急性ST段抬高型心肌梗死患者早期再灌注治疗现状及预后[J].中国急救医学,2021,41(2):122-126.
|
5 |
中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.
|
6 |
Mckavanagh P, Zawadowski G, Cantor WJ. Utilization of PCI after fibrinolysis[M]// Watson TJ, Ong PJL, Tcheng JE, et al. Primary angioplasty: a practical guide. Singapore: Springer, 2018.
|
7 |
Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39 (2): 119-177.
|
8 |
中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2021概要[J].中国循环杂志,2022,37(6):553-578.
|
9 |
Bolognese L. Treatment of ST-elevation myocardial infarction: state of the art and new horizons[J]. G Ital Cardiol (Rome), 2021, 22 (3): 167-180.
|
10 |
Geng W, Zhang Q, Liu J, et al. A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction[J]. J Interv Cardiol, 2018, 31 (2): 136-143.
|
11 |
孙冰,王海昌,孙冬冬.急性ST段抬高型心肌梗死溶栓治疗的最新进展[J].心脏杂志,2020,32(1):93-98.
|
12 |
McCaetney PJ, Eteiba H, Maznyczka AM, et al. Effect of low-dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: a randomized clinical trial[J]. JAMA, 2019, 321 (1): 56-68.
|
13 |
Liu Y, Yang Y, Li Y, et al. Comparison of efficacy and safety of recombinant human prourokinase and alteplase in the treatment of STEMI and analysis of influencing factors of efficacy[J]. Evid Based Complement Alternat Med, 2021 (2021): 6702965.
|
14 |
Zhao L, Zhao Z, Chen X, et al. Safety and efficacy of prourokinase injection in patients with ST-elevation myocardial infarction: phase IV clinical trials of the prourokinase phase study[J]. Heart Vessels, 2018, 33 (5): 507-512.
|
15 |
Pu J, Ding S, Ge H, et al. Efficacy and safety of a pharmaco-invasive strategy with half-dose alteplase versus primary angioplasty in ST-segment-elevation myocardial infarction: EARLY-MYO trial (early routine catheterization after alteplase fibrinolysis versus primary PCI in acute ST-segment-elevation myocardial infarction)[J]. Circulation, 2017, 136 (16): 1462-1473.
|
16 |
Jiang W, Xiong X, Du X, et al. Safety and efficacy study of prourokinase injection during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction[J]. Coron Artery Dis, 2021, 32 (1): 25-30.
|
17 |
Huang D, Qian J, Liu Z, et al. Effects of intracoronary pro-urokinase or tirofiban on coronary flow during primary percutaneous coronary intervention for acute myocardial infarction: a multi-center, placebo-controlled, single-blind, randomized clinical trial[J]. Front Cardiovasc Med, 2021 (8): 710994.
|